Answers are grounded in this paper and cite their sources.
Comparative evidence for non-factor prophylaxis in hemophilia B remains limited. We searched PubMed, CENTRAL, and ClinicalTrials.gov through December 2025 and performed a network meta-analysis of seven trials involving 148 participants. Among patients without inhibitors, mean differences (MDs) versus on-demand treatment for marstacimab, fitusiran, and concizumab were − 30.18 (− 38.03 to − 22.33), − 17.60 (− 31.52 to − 3.68), and − 8.60 (− 15.46 to − 1.74) for annualized spontaneous bleeding rate (AsBR); − 31.67 (− 39.27 to − 24.07), − 18.60 (− 30.71 to − 6.49), and − 9.90 (− 19.35 to − 0.45) for annualized joint bleeding rate (AjBR); and − 27.00 (− 37.31 to − 16.69), − 24.60 (− 39.21 to − 9.99), and − 11.70 (− 21.22 to − 2.18) for annualized bleeding rate (ABR). Among patients with inhibitors, MDs were − 14.40 (− 30.00 to 1.20), − 11.78 (− 30.92 to 7.36), and − 9.74 (− 21.80 to 2.31) for AsBR; − 14.05 (− 22.81 to − 5.29), − 7.00 (− 17.21 to 3.21), and − 7.53 (− 14.88 to − 0.18) for AjBR; and − 20.49 (− 33.62 to − 7.36), − 17.20 (− 33.99 to − 0.41), and − 10.10 (− 19.39 to − 0.82) for ABR. Pooled hemophilia A/B analyses found no significant differences in serious adverse or thromboembolic events. All therapies reduced bleeding compared with on-demand treatment, but comparative superiority was not established. Indirect estimates should be interpreted cautiously because of clinical heterogeneity, limited evidence, and uncertain thrombotic safety.
No takes yet. Share an insight, caveat, or question.
Alashqar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: